BioGaia AB (publ) (LON:0GTN)

Market Cap	814.26M
Revenue (ttm)	115.46M
Net Income (ttm)	24.94M
Shares Out	n/a
EPS (ttm)	0.25
PE Ratio	32.65
Forward PE	25.83
Dividend	0.54 (0.54%)
Ex-Dividend Date	May 8, 2025

Volume	11,239
Average Volume	21,919
Open	100.30
Previous Close	100.19
Day's Range	99.00 - 100.30
52-Week Range	93.60 - 134.60
Beta	0.44
RSI	46.12
Earnings Date	Feb 12, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GTN

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK